News

Data presented at the Child Neurology Society Annual Meeting suggest that the safety and efficacy of cannabidiol (Epidiolex; GW Pharmaceuticals) is maintained through 72 weeks of treatment for patients with LGS.

The drug is now approved to treat pediatric patients with both upper and lower limb spasticity, excluding spasticity caused by cerebral palsy.

VTS-72 is a proprietary combination of fumarate and VTS-Aspirin believed to improve the pharmacokinetics of fumaric acid while improving flush, which is estimated to occur in up to 40% of patients on a fumarate agent.

The drug recently gained FDA approval for treatment of lower limb spasticity in pediatric patients without cerebral palsy, in which it is associated with improved functional outcomes.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic laid out these challenges that he and his colleagues face in differentiating patients with Lewy body dementia from other dementia pathologies.

The agency sent a joint letter with the FTC to Rooted Apothecary LLC for claiming its CBD products can medically treat a number of conditions including Alzheimer disease and Parkinson disease. Since 2017, the FDA has issued more than 10 such letters.

The associate professor of clinical pediatrics and neurology at Ohio State University and section chief of pediatric neurology at Nationwide Children’s Hospital stresses the importance of broadcasting correct information to the public concerning epilepsy.

A pooled analysis of 2 phase 3 trials of fenfluramine demonstrate the clinical potential of the drug for patients with Dravet syndrome.

SynapCell and Motac Neuroscience recently announced a novel biomarker, BetaPark [evo], for Parkinson disease progression. The chief innovation officer at SynapCell provided insight into the clinical implications of this discovery.

The director of the Center for Spinal Cord Injury Research and co-director of the Spinal Cord Injury Model System Center at Kessler Foundation shared his unique perspective on spinal cord injury as someone who experienced it.

Ganaxolone proves effective in phase 2 trial in patients with status epilepticus, with a median time to status cessation of 5 minutes.

The section chief of pediatric neurology at Nationwide Children’s Hospital discusses the realities parents face when exploring CBD to treat epilepsy.

After pulling the plug on trials in March 2019, Biogen has announced that an expanded analysis revealed significant positive results for aducanumab in patients with early Alzheimer disease.

Mia Minen, MD, MPH, sat down for an interview to discuss why behavioral therapies could be an effective and easily accessible treatment for posttraumatic headaches following events like concussions.

The wrist-worn wearable neuromodulation device for essential tremor was shown to be safe and efficacious in the PROSPECT trial, with more than 50% of patients experiencing a ≥50% improvement in tremor "power" or severity.

Partnership between NIH and NINDS hopes to identify disease biomarkers and spur new clinical trials for frontotemporal lobar degeneration.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine offered her perspective on the adherence challenges in treating obstructive sleep apnea with continuous positive airway pressure.

The VMAT2 inhibitor marketed as Austedo by Teva Pharmaceuticals was associated with clinically meaningful long-term treatment benefit in patients with tardive dyskinesia, showing higher response rates than those observed in short-term trials.

At the 2019 American Academy of Neurology Conference, Mia Minen, MD, MPH took the time to sit down and discuss the behavioral therapies associated with treating migraine.

New study results suggest that a wearable ECG device can predict nonconvulsive seizures with a sensitivity of 93.1% and all seizures with a sensitivity of 90.5%.

Neurology News Network for the week ending October 19, 2019.

At the 2019 American Academy of Neurology Annual Meeting, Mia Minen, MD, MPH, discussed the opportunities that the increasing number of mobile health users presents for migraine treatment.

The director of pediatric epilepsy at Northeast Regional Epilepsy Group and co-director of epileptology at Hackensack University Medical Center provided context to these findings to explain how soticlestat can address challenges in developmental epileptic encephalopathies, as well as what may be next in its advancement.

The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine provided her perspective on the differences in OSA prevalence for men and women.

New trials and research partnerships have launched with hopes to find answers for the terminal disease.

The director of the Center for Spinal Cord Injury Research and co-director of the Spinal Cord Injury Model System Center at Kessler Foundation shared insight into the work the center is doing to address the secondary complications and challenges faced by individuals with spinal cord injury.

The director of pediatric epilepsy at Northeast Regional Epilepsy Group and co-director of epileptology at Hackensack University Medical Center spoke about soticlestat and what can be gleaned from data thus far.

Sperling sat down with NeurologyLive at AAIC 2019 to discuss her thoughts on efforts to detect and treat Alzheimer early on in the disease.